Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kashiwa-city, Japan Clinical Trials

A listing of Kashiwa-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (29) clinical trials

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

No formal statistical hypothesis will be tested for safety endpoints in this trial. Based on the well tolerated safety profile from a global phase 3 study, it is hypothesized that talimogene laherparepvec will be safe and well tolerated in Japanese subjects with unresectable Stage IIIB-IVM1c melanoma. A DRR is hypothesized ...

Phase

3.0 miles

Learn More »

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

This is a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study will assess primarily the safety and tolerability and then the efficacy of PDR001 in combination with regorafenib. Particular attention will be paid to the ...

Phase

3.0 miles

Learn More »

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies.

Phase

3.0 miles

Learn More »

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.

Phase

3.0 miles

Learn More »

Study Evaluating Safety Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer. AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE) targeting delta-like protein 3 (DLL3)

Phase

3.0 miles

Learn More »

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with gefitinib in the study population and to determine the recommended dose for expansion of DS-1205c when combined with gefitinib in the study ...

Phase

3.0 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

The drug being tested in this study is called TAK-228. TAK-228 is being tested to treat East Asian participants with advanced nonhematological malignancies for whom standard anticancer treatment is not available or is no longer effective. This study will assess the safety, tolerability, PK and will determine the RP2Ds of ...

Phase

3.0 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of JNJ-63723283 an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).

Phase

3.0 miles

Learn More »

A Study of LY3415244 in Participants With Advanced Solid Tumors

The goal of this study is to evaluate the safety of LY3415244 administered as monotherapy to participants with advanced solid tumors.

Phase

3.0 miles

Learn More »